Search Results - "Raffini, L J"

Association of thrombophilia and catheter‐associated thrombosis in children: a systematic review and meta‐analysis by Neshat‐Vahid, S., Pierce, R., Hersey, D., Raffini, L. J., Faustino, E. V. S.

“…Essentials It is unclear if thrombophilia increases the risk of catheter‐associated thrombosis in children. We conducted a meta‐analysis on thrombophilia and…”
Get full text

Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L) by George, L A, Thalji, N K, Raffini, L J, Gimotty, P A, Camire, R M

“…Approximately 30% of hemophilia A (HA) and 5% of hemophilia B patients develop inhibitors to protein replacement therapy, and this is the major cause of…”
Get full text

Lack of anti‐factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children by Greene, L. A., Law, C., Jung, M., Walton, S., Ignjatovic, V., Monagle, P., Raffini, L. J.

“…Summary Introduction Enoxaparin is a frequently used anticoagulant in children. Unlike in adults, consensus guidelines recommend therapeutic monitoring to a…”
Get full text

Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres by RAGNI, M. V., FOGARTY, P. J., JOSEPHSON, N. C., NEFF, A. T., RAFFINI, L. J., KESSLER, C. M.

“…Every other day (qod) factor VIII prophylaxis prevents joint bleeds in children with severe haemophilia A. Although three times weekly or qod prophylaxis is…”
Get full text

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study by Young, G., Boshkov, L.K., Sullivan, J.E., Raffini, L.J., Cox, D.S., Boyle, D.A., Kallender, H., Tarka, E.A., Soffer, J., Hursting, M.J.

“…Background An increasing number of pediatric patients suffer from thrombotic events necessitating anticoagulation therapy including heparins. Some such…”
Get full text

Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen‐like FXaI16L by George, L. A., Thalji, N. K., Raffini, L. J., Gimotty, P. A., Camire, R. M.

“…Summary Background Approximately 30% of hemophilia A (HA) and 5% of hemophilia B patients develop inhibitors to protein replacement therapy, and this is the…”
Get full text

Utility of computed tomography of the head following head trauma in boys with haemophilia by WITMER, C. M., RAFFINI, L. J., MANNO, C. S.

“…The most serious site of bleeding for patients with haemophilia is the central nervous system. Intracranial haemorrhage (ICH) in patients with haemophilia can…”
Get full text

Panhandle and Reverse-Panhandle PCR Enable Cloning of Der(11) and Der(other) Genomic Breakpoint Junctions of MLL Translocations and Identify Complex Translocation of MLL, AF-4, and CDK6 by Raffini, Leslie J., Slater, Diana J., Rappaport, Eric F., Lo Nigro, Luca, Cheung, Nai-Kong V., Biegel, Jaclyn A., Nowell, Peter C., Lange, Beverly J., Felix, Carolyn A.

“…We used panhandle PCR to clone the der(11) genomic breakpoint junction in three leukemias with t(4;11) and devised reverse-panhandle PCR to clone the…”
Get full text

Pleiotropic Mutations in the HIV-1 Matrix Protein That Affect Diverse Steps in Replication by Casella, Carolyn R, Raffini, Leslie J, Panganiban, Antonito T

“…The matrix domain of the Gag precursor protein, and the mature matrix protein, which is derived from processing of the Gag precursor, functions in several…”
Get full text

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII by Kearney, Susan, Raffini, Leslie J, Pham, Tan P, Lee, Xin Ying, von Mackensen, Sylvia, Landorph, Andrea, Takedani, Hideyuki, Oldenburg, Johannes

“…Prophylactic treatment regimens lead to improvements in health-related quality-of-life (HRQoL) among individuals with hemophilia. Turoctocog alfa pegol (N8-GP)…”
Get full text

Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia by Niebanck, Alison E, Kwiatkowski, Janet L, Raffini, Leslie J

“…It has been observed that some children with immune-mediated thrombocytopenia (ITP) who are treated with intravenous immunoglobulin (IVIG) experience a decline…”
Get full text